Note 11. Discontinued Operations:

During the quarter ended March 31, 2017, the Company made the decision to discontinue the operations of its wholly-owned subsidiary BDI. BDI had developed a proprietary Enhanced Surface Plasmon Resonance technology platform for the detection of molecular interactions. The decision to adopt this plan was made following an evaluation by the Company’s Board of Directors in January 2017 of the estimated results of operations projected during the near to mid-term period for BDI, including consideration of product development required and updated sales forecasts, and estimated additional cash resources required. The Company substantially disposed of the BDI assets and operations during 2017 by selling the assets and licensing the intellectual property rights. The Company has recognized the exit of BDI in accordance with ASC 205-20, Discontinued Operations. As such, the historical results of BDI, following its 2016 acquisition, have been classified as discontinued operations.

The Company’s historical financial statements have been revised to present the operating results of the BDI business as a discontinued operation. Assets and liabilities related to the discontinued operations of BDI were approximately as follows as of March 31, 2018 (unaudited) and December 31, 2017:

Current Liabilities		March 31, 2018				December 31, 2017
Accounts payable		$	16,000			$	16,000
Accrued expenses			-				28,000
Deferred revenue			-				137,000
Total current liabilities		$	16,000			$	181,000

Summarized results of the discontinued operation are as follows for the three months ended March 31, 2018 and 2017 (unaudited):

		March 31, 2018				March 31, 2017
Revenue		$	137,000			$	13,000
Cost of revenue			41,000				2,000
Gross margin			96,000				11,000
Operating expenses			-				654,000
Operating income (loss)			96,000				(643,000	)
Impairment loss			-				(2,704,000	)
Income (loss) from discontinued operations		$	96,000			$	(3,347,000	)